产品库

Carfilzomib (PR-171),868540-17-4

产品信息
  • 公告提醒:爱必信所有产品和服务仅用于科学研究不用于临床应用及其他用途提供产品和服务也不为任何个人提供产品和服务)!

     

    YZ剂描述:

    产品名称:Carfilzomib (PR-171)

    产品别名:卡非佐米

    英文别名:PR171;PR 171;PR-171

    靶点:Proteasome

    CAS:868540-17-4

    纯度:>98%

    外观:Powder

    保存方法:store at -20℃ for one year(Powder); in DMSO or others solvent store at 2-4℃ for two weeks, at -80℃ for six months.

    描述:

    Carfilzomib (PR-171) is a proteasome inhibitor with IC50 less than 5 nM.

    溶解性:DMSO :47 mg/mL (65.3 mM)

    体外研究:

    Carfilzomib inhibits proliferation in a variety of cell lines and patient-derived neoplastic cells, including multiple myeloma, and induced intrinsic and extrinsic apoptotic signaling pathways and activation of c-Jun-N-terminal kinase (JNK). Carfilzomib reveals enhanced anti-MM activity compared with bortezomib, overcome resistance to bortezomib and other agents, and acts synergistically with dexamethasone (Dex). Carfilzomib shoes preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, with over 80% inhibition at doses of 10 nM. Short exposure to low-dose Carfilzomib leads to preferential binding specificity for the β5 constitutive 20S proteasome and the β5i immunoproteasome subunits. Measurement of caspase activity in ANBL-6 cells pulsed with Carfilzomib reveals substantial increases in caspase-8, caspase-9, and caspase-3 activity after 8 hours, giving a 3.2-, 3.9- and 6.9-fold increase, respectively, over control cells after 8 hours. In carfilzomib pulse-treated cells, the mitochondrial membrane integrity is decreased to 41% (Q1 + Q2), compared with 75% in vehicle-treated control cells. In another study, Carfilzomib has also shown preclinical effectiveness against hematological and solid malignancies. Carfilzomib directly inhibits osteoclasts formation and bone resorption.

    体内研究:Carfilzomib moderately reduces tumor growth in an in vivo xenograft model. Carfilzomib effectively decreases multiple myeloma cell viability following continual or transient treatment mimicking. Carfilzomib increases trabecular bone volume, decreases bone resorption and enhances bone formation in non-tumor bearing mice.

    产品信息订购:

      产品货号   产品名称   规格 价格 大包装及货期
      abs810437   Carfilzomib (PR-171)   5mg  900   立即咨询

    产品更多信息请进入爱必信网站咨询

    温馨提示:不可用于临床ZL。
  • 信息声明:本产品供应信息由仪器网为您整合,供应商为(爱必信(上海)生物科技有限公司),内容包括 (Carfilzomib (PR-171),868540-17-4)的品牌、型号、技术参数、详细介绍等;如果您想了解更多关于 (Carfilzomib (PR-171),868540-17-4)的信息,请直接联系供应商,给供应商留言!
    供应商产品推荐
      您可能感兴趣的产品